Cost, quality of life and outcome measures in ovarian cancer

Anti-Cancer Drugs

Volumn 9, Issue 10, 1998, Pages 859-867

  Abbas, Fouad M ^b   Sert, M Bilal ^a  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b SINAI HOSPITAL OF BALTIMORE   (United States)

Author keywords

Assessment; Cost; Measure; Outcome; Ovarian cancer; Quality of life

Indexed keywords

ARTICLE; CANCER SCREENING; CANCER SURVIVAL; CAREGIVER; FAMILY; FEMALE; HEALTH CARE COST; HEALTH STATUS; HUMAN; OVARY CANCER; PERFORMANCE; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0032410250     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199811000-00005     Document Type: Article

References (86)

1. Wingo PA, Tong T, Bolden S. Cancer statistics 1995. CA Cancer J Clin 1995; 45: 8-30.
2. Silverberg E, Boring C, Squires T. Cancer statistics 1990. CA Cancer J Clin 1990; 40: 9-26.
3. Parker SL, Tong T, Bolden S, et al. Cancer statistics 1997. CA Cancer J Clin 1997; 47: 5-27.
4. Tobias JS, Griffiths CT. Management of ovarian carcinoma. N Eng J Med 1976; 249: 818-23; 877-82.
5. Reed E, Janik G, Bookarman N, et al. High-dose carboplatinum and rh-GMCSF in refractory ovrian cancer. Proc Am Soc Clin Oncol 1990; 9: 609 (abstr).
6. Hayes DM, Cvitkovic E, Golbey RB, et al. High dose cisplatinum diamine dichloride amelioration of renal toxicity by Manitel diuresis. Cancer 1977; 39: 1372-75.
7. Salem P, Hall FW, Benjamin RS, et al. Clinical phase I-II study of cisdichlordiamine platinum (II) given by continuous IV infusion. Cancer Treat Rep Response 1978; 62: 1553-5.
8. Willemse HB, Boonstra H, de Vries E. Chemotherapy doseescalation with hemopoietic growth factor support in ovarian cancer. Semin Oncol 1994; 21: 44-50 (suppl 16).
9. Biesma B, Vellenga E, Willemse P, et al. Effects of hemopoietic growth factors on chemotherapy induced myelosuppression. Crit Rev Oncol Hematol 1992; 13: 107-34.
10. Alberts DS, Noel JK. Cisplatin associated neurotoxicity; can it be prevented? Anti-Cancer Drugs 1995; 6: 369-83.
11. McGuire WP, Hoskins WJ, Brady MF, et al. A phase III trial comparing cisplatin/cytoxan and cisplatin/taxol in advanced ovarian cancer. Proc Am Soc Clin Oncol 1993; 12: 255 (abstr).
12. Mandelblatt J, Fahs M. Cost-effectiveness of cervical cancer screening for low income elderly women. J Am Med Ass 1988; 259: 2409-13.
13. Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Disseminated germ cell tumors; chemotherapy with cisplatinum plus Bleomycin plus either vinblastin or etoposide. N EngJ Med 1987; 316: 1434-40.
14. Loehrer PJ, Elson P, Johnson DH, et al. Randomized trial of cisplatinum plus etoposide with or without belomycin in favorable prognosis disseminated germ cell tumors: an ECOG study. Proc Am Soc Clin Oncol 1991; 10: 169-71.
15. Fishman DA, Weinstein J, Bennett C, Lurain J, Calhoun E. Perceptions of Cisplatin related toxicity among ovarian cancer patients and gynecologic oncologists. Proc Soc Gynecol Oncol 29 68 (abstr 29).
16. Oncology Nursing Society Board of Directors, Kathi M Mooney, RN, PhD, FAAN, AOCN, President. Oncology-Nursing Society position paper on quality cancer care. Oncol Nursing Forum 1997; 24: 951-53.
17. Anonymous. Oncology Society Nursing Society position paper on quality care. Oncol Nursing Forum 1997; 24: 951-953.
18. Bland KI. Quality of life management of cancer patients. Cancer 1997; 47: 194-7.
19. Mandelblatt J, Freeman H, Winczewski D, et al. The costs and effects of cervical and breast cancer screening in a public hospital emergency room. The Cancer Control Center of Harlem. AmJ Public Health 1997; 87: 1182-9.
20. Piver MS, Lele SB, Bowlow JJ. Preoperative and intraoperative evaluation in ovarian cancer malignancy. Obstet Gynecol 1976; 48: 312-6.
21. Griffiths CT, Parker L. Cancer of the ovary. In: Knapp RC, Berkowitz RS, eds. Gynecological oncology. New York: MacMillan 1986: 333-6.
22. Jacobs I, et al. Multimodal approach to screening for ovarian cancer. Lancet 1988; ii: 268-72.
23. van Nagell Jr, JR, DePriest PD, Puls E, et al. Ovarian cancer screening in asymptomatic postmenopausal women by transvaginal sonography. Cancer 1991; 68450-62.
24. NIH Consensus Development Conference Panel. Ovarian cancer screening, treatment, and follow up. NIH Consensus Statement 12, 5-7 April, 1994.
25. Bombard AT, Fields AL, Aufox S, Ben-Yishay M. The genetics of ovarian canter: an assessment of current screening protocols and recommendations for counseling families at risk. Clin Obstet Gynecol 1996; 39: 860-72.
26. Piver MS. Routine ovarian cancer screening for a subset of at-risk women. We Female Patient 1997; 22: 71-87.
27. Mettlin C, Murphy GP, Babaian RJ, et al. Results of five year early prostate cancer detection intervention. Cancer 1996; 77: 150-9.
28. Sickles EA. Quality assurance: how to audit your own mammography practice. Radiol Clin N Am 1992; 30: 265-75.
29. Evans WK. Cost-effectiveness of gemcitabine in stage IV non-small cell lung cancer; an estimate using the Population Health Model lung cancer module. Semin Oncol 1997; 24 (2 Suppl 7): S7-56-63.
30. Covens A, Boucher S, Roche K, et al. Is Paclitaxel and Cisplatin a cost-effective first-line therapy for advanced ovarian carcinoma? Cancer 1996; 77: 2086-91.
31. Messori A, Trippoli S, Becagli P, Tendi E. Pharmacoeconomic profile of paclitaxel as a first-line treatment for patients with advanced ovarian carcinoma: a lifetime cost-effectiveness analysis. Cancer 1996; 78: 2366-73.
32. Buller R, Vasilev S, DiSaia P. CA125 kinetics: A cost-effective clinical tool to evaluate clinical trial outcomes in the 1990's. Am J Obstet Gynecol 1996; 174: 1241-54.
33. Ubel P, DeKay M, Baron J, Asch D. Cost-effectiveness analysis in a setting of budget constraints. New Eng J Med 1996; 354: 1174-7.
34. Etzioni R, Urban N, Baker M. Estimating the costs attributable to a disease with application to ovarian cancer. Clin Epidemiol 1996; 49: 95-103.
35. Abbas F, Sert M, Rosenshein N, Zahyrak M, Currie J. Gynecologic oncology patients in the Surgical ICU: impact on outcome. J Reprod Med 1997; 47: 173-8.
36. Abbas F, Sert M, Rosenshein N, Zahyrak M, Currie J. Prolonged stays of OB/GYN patients in the Surgical Intensive Care Unit: a cost-benefit analysis. J Reprod Med 1997; 42: 179-83.
37. Tchekmedyian NS, Cella DF, Winn P, eds. Economical quality of life outcomes in oncology. Oncology 1995; 9(11): suppl.
38. Donovan K, Samson-Fischer RW, Redmann S. Measuring quality of life in cancer patients. J Clin Oncol 1989; 7: 959-68.
39. Feinstein AR. Clinimetrics. New Haven, CT: Yale University Press 1987.
40. Anderson RB. Testa MA. Symptom distress checklists as a component of quality-of-life measurement: comparing prompted reports by patient and physician with concurrent adverse event reports via the physician. Drug Inf J 1994; 28: 89-114.
41. Lord FM. Application of item response theory to practical testing problems. Hillsdale, NJ: Lawrence Erlbaum 1980.
42. Ware JE Jr, Kosinski M, Keller SD. SF-36, physical and mental health summary scales: a user's manual. The Health Institute. New England Medical Center 1994.
43. Testa M, Simonson D. Assessment of quality-of-life outcomes. A Engl J Metl 1996; 33, 835-9.
44. Aaronson NK, Ahmedzai S, Bergman H, et al. The European Organization for the Research and Treatment of Cancer QLA-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-76.
45. Schipper H, Glinch J, McMurray A, Lewis M. Measuring the quality of life of cancer patients. The Functional Living Index - Cancer: development and validation. J Clin Oncol 1984; 2: 472-83.
46. Ware JF, Sherbourne CD. The MOS 36 Item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992; 30: 473-83.
47. McHorney CA, Ware JF, Rogers W. et al. The validity and relative precision of MOS short- and long-form Health Status Scales and Dartmouth COOP Charts: results from the Medical Outcomes Study. Med Care 1992; 30: 253-65 (suppl 5).
48. Camphell A, Converse PE, Rodgers WL. The quality of American life. New York: Sage 1976.
49. Till JE, McNeil BJ, Rush RS. Measurements of multiple components of quality of life Cancer Treat Symp 1984; 1: 177-81.
50. Bergner J, Bobbitt RA, Carter WB, Gibson BS. The Sickness Impact Profile. Development and final revision of a health status measure Med Care 1981; 19: 787-806.
51. Drummond MF, Stoddart GL, Torrance GW. Methods for economic evaluation of health care programmes. Oxford: Oxford University Press 1987.
52. Gelber RD, Goldhirsch A, Cavalli F. Quality-of-life adjusted evaluation of adjuvant therapies for operable breast cancer. Ann Intern Med 1991; 114: 621-8.
53. Slevin MI, Plant H, Lynch D, et al. Who should measure quality of life, the doctor or the patient? Br J Cancer 1988; 57: 109.
54. Nunnally JC. Psychometric theory. New York: McGraw-Hill 1967.
55. Mor V. Cancer patients quality of life over the disease course: lessons from the real world. J Chron Dis 1987; 40: 535.
56. Ferrans CE. Development of a Quality of Life Index for patients with cancer. Oncol Nursing Forum 1990; 17: 15-21 (suppl).
57. Granai C., Gajewski W, Falkenberry S, et al. Can we do more, complementing care (e.g. massage therapy, pet companionship) integrated with chemotherapy. The patient's perspective. Proc Soc Gynecol Oncol 29: 68 (abstr 30).
58. Messias DK, Yeager KA, Dibble SI, Dodd MJ. Patients perspectives of fatigue while undergoing chemotherapy. Oncol Nursing Forum 1997; 24: 43-8.
59. Kalman D, Villani LJ. Nutritional aspects of cancer-related fatigue. J Am Dietitic Ass 1997; 97: 650-4
60. Erlick-Robinson G, Rosen BP, Bradley LN, et al. Psychological impact of screening for familial ovarian cancer; reactions to initial assessment. Gynecol Oncol 1997; 65: 197-205.
61. Hack TF, Degner LF, Dyck DG. Relationship between preferences for decisional control and illness information among women with breast cancer: a quantitative and qualitative analysis. Soc Sci Med 1994; 39: 279-89.
62. Bennahum DA, Forman WB, Vellas B, Albarede JL. Life expectancy, co-morbidity, and quality of life. A framework of reference for medical decisions. Clin Geriat Med 1997; 13: 33-53.
63. McMillan SC. The quality of life of patients with cancer receiving hospice care. Oncol Nursing Forum 1996; 23: 1221-8.
64. Larsen J, Gardulf A, Nordstrom G, Bjorkstrand B. Ljungman P. Health-related quality of life in women with breast cancer undergoing stem cell transplantation. Cancer Nursing 1996; 19: 368-75.
65. Wyatt G, Friedman LL. Long-term female cancer survivors: quality of life issues and clinical implications. Cancer Nursing 1996; 19: 1-7.
66. Smith SL. Physical exercise as an oncology nursing intervention to enhance quality of life. Oncol Nursing Forum 1996, 23: 771-8.
67. Kosmidis P. Quality of life as a new end point. Chest 1996; 109 (5 suppl): 110S-2.
68. Constitution of the World Health Organization. In: World Health Organization. Handbook of basic documents, 5th edn. Geneva: Palais des Nations 1952: 3-20.
69. Their SO. Forces motivating the use of health status assessment measures in clinical settings and related clinical research. Med Care 1992; 30 (suppl): MS15-22.
70. Patrick DL, Bush JW, Chen MM. Toward an operational definition of health. J Health Soc Behav 1973; 14: 6-23.
71. Brook RH, Ware JE Jr, Rogers WH, et al. Does free care improve adults' health? Results from a randomized, controlled trial. N Eng J Med 1983, 309: 1426-34.
72. Bergner M. Quality of life, health status, and clinical research. Med Care 1989; 27 (suppl): S148-56.
73. Patrick DL, Erickson P. Concepts of health-related quality of life. In. Patrick DL, Erickson P, eds. Health status and health policy; quality of life in health care evaluation and resource allocation. New York: Oxford university Press 1993: 76-112.
74. Anderson B, Lutgendorf S, Quality of life in gynecologic cancer survivors. CA Cancer J Clin 1997; 47: 218-225.
75. Anderson B, LaPolla J, Turner D, et al. Ovarian transposition in cervical cancer. Gynecol Oncol 1993; 49: 206-14.
76. Anderson BL, Lachenbruch PA, deProsse C. Controlled prospective longitudinal study of women with cancer II: psychological outcomes. J Consult Clin Psychol 1989; 57: 692-7.
77. Anderson BL, Anderson B, deProsse C. Controlled prospective longitudinal study of women with cancer: I. Sexual functioning outcomes. J Consult Clin Psychol 1989; 57: 683-91.
78. Anderson BL, Lachenbruch PA, Anderson B, et al. Sexual dysfunction and signs of gynecologic cancer. Cancer 1986; 57: 1880-6.
79. Connelly E, Markman M, Kennedy A, et al. Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity. Gynecol Oncol 1996; 62: 166-8.
80. Hergner M, Bobbin RA, Carter WH, Gibson BS. The sickness impact profile: development and final revision of a health status measure. Med Care 1981; 19: 787-805.
81. Erlick-Robinson G, Rosen BP, Bradley LN, et al. Psychological impact of screening for familial ovarian cancer; reactions to initial assessment. Gynecol Oncol 1997; 65: 197-205.
82. Ellwood P. Outcomes management: a technology of patient experience. The Shattuck Lecture. N Engl J Med 1988; 318: 1549-56.
83. Relman A. Assessment and accountability: the third revolution in medicine. N Engl J Med 1988; 319: 1220-2.
84. Reemtsma K, Morgan M. Outcomes assessment: a primer. Bull Am Coll Surg 1997; 82: 34-9.
85. Kennedy AW. Outcomes management: an opportunity for our future. Gynecol Oncol 1996; 63: 157-8.
86. Morris M, Levenback C, Burke T, Dejesus Y, Lucas K, Gershenson D. An outcomes management program in gynecologic oncology. Obstet Gynecol 1997; 89: 485-92.